Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug maintenance study in moderately to severely active Crohn's disease
NL-OMON59106Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of duvakitug in Crohn's disease (3 arms), sponsored by Sanofi. Primary endpoints: Clinical remission by CDAI at Week 40, Endoscopic response by SES-CD at Week 40 and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
duvakitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59106.